Today: 12 June 2026
Browse Category

NASDAQ:TERN 16 December 2025 - 12 May 2026

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals shares traded at $52.86 in U.S. premarket Thursday, just below Merck’s $53-per-share cash offer after Merck agreed to acquire the company for about $6.7 billion. The deal centers on Terns’ leukemia drug TERN-701, which showed a 75% major molecular response rate in early trials. The offer requires over 50% of shares tendered and antitrust approval. Terns would owe Merck $235 million if it accepts a higher bid.
26 March 2026
···
Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck will acquire Terns Pharmaceuticals for $53 per share in cash, valuing the company at about $6.7 billion. The deal gives Merck rights to TERN-701, an experimental leukemia drug, as it prepares for Keytruda’s patent expirations in 2028. The offer represents a 6% premium to Terns’ last close and is subject to antitrust review and shareholder approval. Merck expects to close the transaction in the second quarter.
25 March 2026
··
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

Terns Pharmaceuticals shares fell to $39.62 on Dec. 18 after opening near $42.55, following weeks of sharp gains driven by positive TERN-701 trial data in chronic myeloid leukemia. The company reported a 74% major molecular response rate at 24 weeks in its Phase 1 trial and selected doses for Phase 2 expansion. Trading volume topped 2 million shares.
18 December 2025
··

Stock Market Today

  • Keel Infrastructure Stock Rises After $458 Million Convertible Notes Deal Boosts AI Data Center Prospects
    June 12, 2026, 8:39 AM EDT. Keel Infrastructure Corp. shares gained after the company closed a $458 million convertible senior notes deal, expanding from an initial $350 million offering. The financing enhances Keel's liquidity as it shifts focus from Bitcoin mining to AI and high-performance computing (HPC) data centers. Convertible notes are debt instruments that can convert to equity, potentially diluting shares but providing capital for growth. Market attention centers on whether Keel can secure leases at its Panther Creek, Sharon, and Moses Lake sites, critical to unlocking future cash flows. CEO Ben Gagnon targets signing three leases by year-end, aiming to attract investment-grade tenants and validate the company's valuation beyond mining economics. The stock closed up 5.14% at $5.52 on June 11 and traded higher premarket June 12, reflecting investor optimism amid scarce power-ready data center assets.

Latest articles

Micron Stock Nears $1,000 Again as AI Memory Rally Faces June 24 Test

Micron Stock Nears $1,000 Again as AI Memory Rally Faces June 24 Test

12 June 2026
Micron soared 11.66% to $995.87 after a sharp pullback, as investors weigh booming AI-driven memory demand against concerns the stock already prices in a near-perfect upcycle; all eyes are on the June 24 earnings call, with analysts forecasting Q3 EPS of $19.46 on $34.07B revenue and debating whether supply constraints can sustain elevated earnings and justify Micron’s $1.14T valuation.
Go toTop